Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma.

<h4>Introduction</h4>Methods used for epidermal growth factor receptor (EGFR) mutation testing vary widely. The impact of detection methods on the rates of response to EGFR-tyrosine kinase inhibitors (TKIs) in EGFR-wild type (wt) lung adenocarcinoma patients is unknown.<h4>Methods&...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jeng-Sen Tseng, Chih-Liang Wang, Ming-Shyan Huang, Chung-Yu Chen, Cheng-Yu Chang, Tsung-Ying Yang, Chi-Ren Tsai, Kun-Chieh Chen, Kuo-Hsuan Hsu, Meen-Hsin Tsai, Sung-Liang Yu, Kang-Yi Su, Chih-Wei Wu, Cheng-Ta Yang, Yuh-Min Chen, Gee-Chen Chang
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2014
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/f321764dc4834253830724de3df3add0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f321764dc4834253830724de3df3add0
record_format	dspace
spelling	oai:doaj.org-article:f321764dc4834253830724de3df3add02021-11-25T06:00:48ZImpact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma.1932-620310.1371/journal.pone.0107160https://doaj.org/article/f321764dc4834253830724de3df3add02014-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0107160https://doaj.org/toc/1932-6203<h4>Introduction</h4>Methods used for epidermal growth factor receptor (EGFR) mutation testing vary widely. The impact of detection methods on the rates of response to EGFR-tyrosine kinase inhibitors (TKIs) in EGFR-wild type (wt) lung adenocarcinoma patients is unknown.<h4>Methods</h4>We recruited the Group-I patients to evaluate the efficacy of erlotinib in patients with EGFR-wt lung adenocarcinoma by either direct sequencing (DS) or mutant type-specific sensitive (MtS) methods in six medical centers in Taiwan. Cross recheck of EGFR mutations was performed in patients who achieved objective response to erlotinib and had adequate specimens. The independent Group-II lung adenocarcinoma patients whose EGFR mutation status determined by DS were recruited to evaluate the potential limitations of three MtS methods.<h4>Results</h4>In Group-I analysis, 38 of 261 EGFR-wt patients (14.6%) achieved partial response to erlotinib treatment. Nineteen patients (50.0%) had adequate specimens for cross recheck of EGFR mutations and 10 of them (52.6%) had changes in EGFR mutation status, 5 in 10 by DS and 5 in 9 by MtS methods originally. In Group-II analysis, 598 of 996 lung adenocarcinoma patients (60.0%) had detectable EGFR mutations. The accuracy rates of the three MtS methods, MALDI-TOF MS, Scorpions ARMS and Cobas, were 87.8%, 86.8% and 85.8%, respectively.<h4>Conclusions</h4>A significant portion of the erlotinib responses in EGFR-wt lung adenocarcinoma patients were related to the limitations of detection methods, not only DS but also MtS methods with similar percentages. Prospective studies are needed to define the proper strategy for EGFR mutation testing.Jeng-Sen TsengChih-Liang WangMing-Shyan HuangChung-Yu ChenCheng-Yu ChangTsung-Ying YangChi-Ren TsaiKun-Chieh ChenKuo-Hsuan HsuMeen-Hsin TsaiSung-Liang YuKang-Yi SuChih-Wei WuCheng-Ta YangYuh-Min ChenGee-Chen ChangPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 9, p e107160 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Jeng-Sen Tseng Chih-Liang Wang Ming-Shyan Huang Chung-Yu Chen Cheng-Yu Chang Tsung-Ying Yang Chi-Ren Tsai Kun-Chieh Chen Kuo-Hsuan Hsu Meen-Hsin Tsai Sung-Liang Yu Kang-Yi Su Chih-Wei Wu Cheng-Ta Yang Yuh-Min Chen Gee-Chen Chang Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma.
description	<h4>Introduction</h4>Methods used for epidermal growth factor receptor (EGFR) mutation testing vary widely. The impact of detection methods on the rates of response to EGFR-tyrosine kinase inhibitors (TKIs) in EGFR-wild type (wt) lung adenocarcinoma patients is unknown.<h4>Methods</h4>We recruited the Group-I patients to evaluate the efficacy of erlotinib in patients with EGFR-wt lung adenocarcinoma by either direct sequencing (DS) or mutant type-specific sensitive (MtS) methods in six medical centers in Taiwan. Cross recheck of EGFR mutations was performed in patients who achieved objective response to erlotinib and had adequate specimens. The independent Group-II lung adenocarcinoma patients whose EGFR mutation status determined by DS were recruited to evaluate the potential limitations of three MtS methods.<h4>Results</h4>In Group-I analysis, 38 of 261 EGFR-wt patients (14.6%) achieved partial response to erlotinib treatment. Nineteen patients (50.0%) had adequate specimens for cross recheck of EGFR mutations and 10 of them (52.6%) had changes in EGFR mutation status, 5 in 10 by DS and 5 in 9 by MtS methods originally. In Group-II analysis, 598 of 996 lung adenocarcinoma patients (60.0%) had detectable EGFR mutations. The accuracy rates of the three MtS methods, MALDI-TOF MS, Scorpions ARMS and Cobas, were 87.8%, 86.8% and 85.8%, respectively.<h4>Conclusions</h4>A significant portion of the erlotinib responses in EGFR-wt lung adenocarcinoma patients were related to the limitations of detection methods, not only DS but also MtS methods with similar percentages. Prospective studies are needed to define the proper strategy for EGFR mutation testing.
format	article
author	Jeng-Sen Tseng Chih-Liang Wang Ming-Shyan Huang Chung-Yu Chen Cheng-Yu Chang Tsung-Ying Yang Chi-Ren Tsai Kun-Chieh Chen Kuo-Hsuan Hsu Meen-Hsin Tsai Sung-Liang Yu Kang-Yi Su Chih-Wei Wu Cheng-Ta Yang Yuh-Min Chen Gee-Chen Chang
author_facet	Jeng-Sen Tseng Chih-Liang Wang Ming-Shyan Huang Chung-Yu Chen Cheng-Yu Chang Tsung-Ying Yang Chi-Ren Tsai Kun-Chieh Chen Kuo-Hsuan Hsu Meen-Hsin Tsai Sung-Liang Yu Kang-Yi Su Chih-Wei Wu Cheng-Ta Yang Yuh-Min Chen Gee-Chen Chang
author_sort	Jeng-Sen Tseng
title	Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma.
title_short	Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma.
title_full	Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma.
title_fullStr	Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma.
title_full_unstemmed	Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma.
title_sort	impact of egfr mutation detection methods on the efficacy of erlotinib in patients with advanced egfr-wild type lung adenocarcinoma.
publisher	Public Library of Science (PLoS)
publishDate	2014
url	https://doaj.org/article/f321764dc4834253830724de3df3add0
work_keys_str_mv	AT jengsentseng impactofegfrmutationdetectionmethodsontheefficacyoferlotinibinpatientswithadvancedegfrwildtypelungadenocarcinoma AT chihliangwang impactofegfrmutationdetectionmethodsontheefficacyoferlotinibinpatientswithadvancedegfrwildtypelungadenocarcinoma AT mingshyanhuang impactofegfrmutationdetectionmethodsontheefficacyoferlotinibinpatientswithadvancedegfrwildtypelungadenocarcinoma AT chungyuchen impactofegfrmutationdetectionmethodsontheefficacyoferlotinibinpatientswithadvancedegfrwildtypelungadenocarcinoma AT chengyuchang impactofegfrmutationdetectionmethodsontheefficacyoferlotinibinpatientswithadvancedegfrwildtypelungadenocarcinoma AT tsungyingyang impactofegfrmutationdetectionmethodsontheefficacyoferlotinibinpatientswithadvancedegfrwildtypelungadenocarcinoma AT chirentsai impactofegfrmutationdetectionmethodsontheefficacyoferlotinibinpatientswithadvancedegfrwildtypelungadenocarcinoma AT kunchiehchen impactofegfrmutationdetectionmethodsontheefficacyoferlotinibinpatientswithadvancedegfrwildtypelungadenocarcinoma AT kuohsuanhsu impactofegfrmutationdetectionmethodsontheefficacyoferlotinibinpatientswithadvancedegfrwildtypelungadenocarcinoma AT meenhsintsai impactofegfrmutationdetectionmethodsontheefficacyoferlotinibinpatientswithadvancedegfrwildtypelungadenocarcinoma AT sungliangyu impactofegfrmutationdetectionmethodsontheefficacyoferlotinibinpatientswithadvancedegfrwildtypelungadenocarcinoma AT kangyisu impactofegfrmutationdetectionmethodsontheefficacyoferlotinibinpatientswithadvancedegfrwildtypelungadenocarcinoma AT chihweiwu impactofegfrmutationdetectionmethodsontheefficacyoferlotinibinpatientswithadvancedegfrwildtypelungadenocarcinoma AT chengtayang impactofegfrmutationdetectionmethodsontheefficacyoferlotinibinpatientswithadvancedegfrwildtypelungadenocarcinoma AT yuhminchen impactofegfrmutationdetectionmethodsontheefficacyoferlotinibinpatientswithadvancedegfrwildtypelungadenocarcinoma AT geechenchang impactofegfrmutationdetectionmethodsontheefficacyoferlotinibinpatientswithadvancedegfrwildtypelungadenocarcinoma
_version_	1718414316406833152

Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma.

Ejemplares similares